English

KV PHARMACEUTICAL CO /DE/

EDGAR

Report (type unavailable) · filed 2012-07-31

87 filing records in this dataset, filed from 1995-02-14 to 2012-07-31. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

7.6 million Unit12

2012 Q4 · Unit12

Exact inputs and evidence

Revenue: 23200000 Unit12 Source
Revenue: 15600000 Unit12 Source

Operating margin

-314.47%

2012 Q4 · %

Exact inputs and evidence

Operating Income: -141200000 Unit12 Source
Operating Income: -117300000 Unit12 Source
Revenue: 23200000 Unit12 Source
Revenue: 15600000 Unit12 Source

Operating cash flow

-48.2 million Unit12

2012 Q4 · Unit12

Exact inputs and evidence

Operating Cash Flow: -169300000 Unit12 Source
Operating Cash Flow: -121100000 Unit12 Source

Free cash flow

-48.2 million Unit12

2012 Q4 · Unit12

Exact inputs and evidence

Operating Cash Flow: -169300000 Unit12 Source
Operating Cash Flow: -121100000 Unit12 Source
Capital Expenditure: 100000 Unit12 Source
Capital Expenditure: 100000 Unit12 Source

Cash and cash equivalents: 50.7 million Unit12 2012-03-31 Source
Exact value

50700000 Unit12
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2012-07-31.

Financial data available through: 2012-03-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2012-03-31
Operating income: 3 of 11 periods available· newest 2012-03-31
Net income: 3 of 11 periods available· newest 2012-03-31
Operating cash flow: 3 of 11 periods available· newest 2012-03-31
Capital expenditure: 3 of 11 periods available· newest 2012-03-31
Total assets: 2 of 11 periods available· newest 2012-03-31
Total liabilities: 2 of 11 periods available· newest 2012-03-31
Current assets: 2 of 11 periods available· newest 2012-03-31
Current liabilities: 2 of 11 periods available· newest 2012-03-31
Cash and cash equivalents: 4 of 11 periods available· newest 2012-03-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-15%

Prior period

Unit12 27.3 million

2010-04-01 – 2011-03-31
Current period

Unit12 23.2 million

2011-04-01 – 2012-03-31

Exact inputs and evidence

23200000 − 27300000 = -4100000 Unit12

27300000 Unit12 · 2010-04-01 – 2011-03-31
Inspect prior input Prior source
23200000 Unit12 · 2011-04-01 – 2012-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · KV PHARMACEUTICAL CO /DE/ · 2012-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Year-over-year change in Revenue: -4100000 Unit12 Concept: fundies:Revenue Period: 2011-04-01 to 2012-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 23200000 Unit12 (2011-04-01 to 2012-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1686284 Filing: 000119312512271006 Input fundies:Revenue: 27300000 Unit12 (2010-04-01 to 2011-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1686147 Filing: 000119312512271006
The citation records this snapshot. The page link may show a newer release later.
Net income
+Unit12 169.4 million

Prior period

−Unit12 271.7 million

2010-04-01 – 2011-03-31
Current period

−Unit12 102.3 million

2011-04-01 – 2012-03-31

Exact inputs and evidence

-102300000 − -271700000 = 169400000 Unit12

-271700000 Unit12 · 2010-04-01 – 2011-03-31
Inspect prior input Prior source
-102300000 Unit12 · 2011-04-01 – 2012-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · KV PHARMACEUTICAL CO /DE/ · 2012-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Year-over-year change in Net income: 169400000 Unit12 Concept: fundies:NetIncome Period: 2011-04-01 to 2012-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -102300000 Unit12 (2011-04-01 to 2012-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#808343 Filing: 000119312512271006 Input fundies:NetIncome: -271700000 Unit12 (2010-04-01 to 2011-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#806821 Filing: 000119312512271006
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−Unit12 9.8 million

Prior period

−Unit12 159.5 million

2010-04-01 – 2011-03-31
Current period

−Unit12 169.3 million

2011-04-01 – 2012-03-31

Exact inputs and evidence

-169300000 − -159500000 = -9800000 Unit12

-159500000 Unit12 · 2010-04-01 – 2011-03-31
Inspect prior input Prior source
-169300000 Unit12 · 2011-04-01 – 2012-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · KV PHARMACEUTICAL CO /DE/ · 2012-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Year-over-year change in Operating cash flow: -9800000 Unit12 Concept: fundies:OperatingCashFlow Period: 2011-04-01 to 2012-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -169300000 Unit12 (2011-04-01 to 2012-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#805106 Filing: 000119312512271006 Input fundies:OperatingCashFlow: -159500000 Unit12 (2010-04-01 to 2011-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#804913 Filing: 000119312512271006
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-66.7%

Prior period

Unit12 300,000

2010-04-01 – 2011-03-31
Current period

Unit12 100,000

2011-04-01 – 2012-03-31

Exact inputs and evidence

100000 − 300000 = -200000 Unit12

300000 Unit12 · 2010-04-01 – 2011-03-31
Inspect prior input Prior source
100000 Unit12 · 2011-04-01 – 2012-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · KV PHARMACEUTICAL CO /DE/ · 2012-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Year-over-year change in Capital expenditure: -200000 Unit12 Concept: fundies:CapitalExpenditure Period: 2011-04-01 to 2012-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 100000 Unit12 (2011-04-01 to 2012-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1543527 Filing: 000119312512271006 Input fundies:CapitalExpenditure: 300000 Unit12 (2010-04-01 to 2011-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1543338 Filing: 000119312512271006
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2012 2011-04-01 – 2012-03-31

Revenue Unit12 23.2 million 100% of revenue
Cost of revenue Unit12 2.3 million 9.9% of revenue
Operating expenses Unit12 162.1 million 699% of revenue
Operating income −Unit12 141.2 million −609% of revenue
Tax, interest and other Derived −Unit12 38.9 million −168% of revenue
Net income −Unit12 102.3 million −441% of revenue

Cash

Operating cash flow −Unit12 169.3 million −730% of revenue
Capital expenditure Unit12 100,000 0.4% of revenue
Free cash flow Derived −Unit12 169.4 million −730% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2010 Operating loss: operating costs were 3,455% of revenue.
2011 Operating loss: operating costs were 472% of revenue.
2012 Operating loss: operating costs were 709% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2010 2009-04-01 – 2010-03-31	9100000	314400000 Derived	-305300000	-21700000 Derived	-283600000	-10300000 Derived	Source 2009-04-01 – 2010-03-31: 9100000 Unit12 Inspect Revenue Open source 2009-04-01 – 2010-03-31: -305300000 Unit12 Inspect Operating Income Open source 2009-04-01 – 2010-03-31: -283600000 Unit12 Inspect Net Income Open source 2009-04-01 – 2010-03-31: -100000 Unit12 Inspect Operating Cash Flow Open source 2009-04-01 – 2010-03-31: 10200000 Unit12 Inspect Capital Expenditure Open source
2011 2010-04-01 – 2011-03-31	27300000	128800000 Derived	-101500000	170200000 Derived	-271700000	-159800000 Derived	Source 2010-04-01 – 2011-03-31: 27300000 Unit12 Inspect Revenue Open source 2010-04-01 – 2011-03-31: -101500000 Unit12 Inspect Operating Income Open source 2010-04-01 – 2011-03-31: -271700000 Unit12 Inspect Net Income Open source 2010-04-01 – 2011-03-31: -159500000 Unit12 Inspect Operating Cash Flow Open source 2010-04-01 – 2011-03-31: 300000 Unit12 Inspect Capital Expenditure Open source
2012 2011-04-01 – 2012-03-31	23200000	164400000 Derived	-141200000	-38900000 Derived	-102300000	-169400000 Derived	Source 2011-04-01 – 2012-03-31: 23200000 Unit12 Inspect Revenue Open source 2011-04-01 – 2012-03-31: -141200000 Unit12 Inspect Operating Income Open source 2011-04-01 – 2012-03-31: -102300000 Unit12 Inspect Net Income Open source 2011-04-01 – 2012-03-31: -169300000 Unit12 Inspect Operating Cash Flow Open source 2011-04-01 – 2012-03-31: 100000 Unit12 Inspect Capital Expenditure Open source

Amounts are exact, in Unit12.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit12 23.2M 2012

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit12)	Source evidence
20102010-03-31	Revenue	9100000	Revenue: 9100000 Open source
20112011-03-31	Revenue	27300000	Revenue: 27300000 Open source
20122012-03-31	Revenue	23200000	Revenue: 23200000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-15% 2012

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20102010-03-31	Year over year	No prior comparable period	Revenue: 9100000 Open source
20112011-03-31	Year over year	200%	Revenue: 27300000 Open source Revenue: 9100000 Open source
20122012-03-31	Year over year	-15%	Revenue: 23200000 Open source Revenue: 27300000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -608.6% 2012

Net margin -440.9% 2012

Free cash flow margin -730.2% 2012

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20102010-03-31	Operating margin	-3,354.9%	Operating Income: -305300000 Open source Revenue: 9100000 Open source
20112011-03-31	Operating margin	-371.8%	Operating Income: -101500000 Open source Revenue: 27300000 Open source
20122012-03-31	Operating margin	-608.6%	Operating Income: -141200000 Open source Revenue: 23200000 Open source
20102010-03-31	Net margin	-3,116.5%	Net Income: -283600000 Open source Revenue: 9100000 Open source
20112011-03-31	Net margin	-995.2%	Net Income: -271700000 Open source Revenue: 27300000 Open source
20122012-03-31	Net margin	-440.9%	Net Income: -102300000 Open source Revenue: 23200000 Open source
20102010-03-31	Free cash flow margin	-113.2%	Revenue: 9100000 Open source Operating Cash Flow: -100000 Open source Capital Expenditure: 10200000 Open source
20112011-03-31	Free cash flow margin	-585.3%	Revenue: 27300000 Open source Operating Cash Flow: -159500000 Open source Capital Expenditure: 300000 Open source
20122012-03-31	Free cash flow margin	-730.2%	Revenue: 23200000 Open source Operating Cash Flow: -169300000 Open source Capital Expenditure: 100000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit12 -169.3M 2012

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20102010-03-31	Operating cash flow	-100000	Operating Cash Flow: -100000 Open source
20112011-03-31	Operating cash flow	-159500000	Operating Cash Flow: -159500000 Open source
20122012-03-31	Operating cash flow	-169300000	Operating Cash Flow: -169300000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit12 -169.4M 2012

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20102010-03-31	Free cash flow	-10300000	Operating Cash Flow: -100000 Open source Capital Expenditure: 10200000 Open source
20112011-03-31	Free cash flow	-159800000	Operating Cash Flow: -159500000 Open source Capital Expenditure: 300000 Open source
20122012-03-31	Free cash flow	-169400000	Operating Cash Flow: -169300000 Open source Capital Expenditure: 100000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

289.7% 2012

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2010-03-31	Liabilities / assets	Not reported	No source recorded
20112011-03-31	Liabilities / assets	166.9%	Total Liabilities: 942500000 Open source Total Assets: 564700000 Open source
20122012-03-31	Liabilities / assets	289.7%	Total Liabilities: 734100000 Open source Total Assets: 253400000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.61× 2012

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2010-03-31	Current assets / current liabilities	Not reported	No source recorded
20112011-03-31	Current assets / current liabilities	1.32×	Current Assets: 347900000 Open source Current Liabilities: 263000000 Open source
20122012-03-31	Current assets / current liabilities	0.61×	Current Assets: 104300000 Open source Current Liabilities: 172000000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2010 2009-04-01 – 2010-03-31	−Unit12 283.6 million Exact value Exact value: -283600000 Unit12 2009-04-01 – 2010-03-31: -283600000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · KV PHARMACEUTICAL CO /DE/ · 2010-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Net Income: -283600000 Unit12 Concept: fundies:NetIncome Period: 2009-04-01 to 2010-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055/explain?concept=fundies%3ANetIncome&period=2010-03-31&surface=latest&period_type=duration&start=2009-04-01&unit=Unit12&dimensions= Input fundies:NetIncome: -283600000 Unit12 (2009-04-01 to 2010-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#805299 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.	−Unit12 100,000 Exact value Exact value: -100000 Unit12 2009-04-01 – 2010-03-31: -100000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KV PHARMACEUTICAL CO /DE/ · 2010-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Operating Cash Flow: -100000 Unit12 Concept: fundies:OperatingCashFlow Period: 2009-04-01 to 2010-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055/explain?concept=fundies%3AOperatingCashFlow&period=2010-03-31&surface=latest&period_type=duration&start=2009-04-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -100000 Unit12 (2009-04-01 to 2010-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#804723 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.	Unit12 10.2 million Exact value Exact value: 10200000 Unit12 2009-04-01 – 2010-03-31: 10200000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KV PHARMACEUTICAL CO /DE/ · 2010-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Capital Expenditure: 10200000 Unit12 Concept: fundies:CapitalExpenditure Period: 2009-04-01 to 2010-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055/explain?concept=fundies%3ACapitalExpenditure&period=2010-03-31&surface=latest&period_type=duration&start=2009-04-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 10200000 Unit12 (2009-04-01 to 2010-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1543147 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.	−Unit12 10.3 million Calculation and evidence -100000 − 10200000 Unit12 Exact free cash flow: -10300000 Unit12 2009-04-01 – 2010-03-31: -100000 Unit12 · Inspect Operating Cash Flow · Source 2009-04-01 – 2010-03-31: 10200000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KV PHARMACEUTICAL CO /DE/ · 2010-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Free cash flow: -10300000 Unit12 Concept: free-cash-flow Period: 2009-04-01 to 2010-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -100000 Unit12 (2009-04-01 to 2010-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#804723 Filing: 000119312512271006 Input fundies:CapitalExpenditure: 10200000 Unit12 (2009-04-01 to 2010-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1543147 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.
2011 2010-04-01 – 2011-03-31	−Unit12 271.7 million Exact value Exact value: -271700000 Unit12 2010-04-01 – 2011-03-31: -271700000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · KV PHARMACEUTICAL CO /DE/ · 2011-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Net Income: -271700000 Unit12 Concept: fundies:NetIncome Period: 2010-04-01 to 2011-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055/explain?concept=fundies%3ANetIncome&period=2011-03-31&surface=latest&period_type=duration&start=2010-04-01&unit=Unit12&dimensions= Input fundies:NetIncome: -271700000 Unit12 (2010-04-01 to 2011-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#806821 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.	−Unit12 159.5 million Exact value Exact value: -159500000 Unit12 2010-04-01 – 2011-03-31: -159500000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KV PHARMACEUTICAL CO /DE/ · 2011-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Operating Cash Flow: -159500000 Unit12 Concept: fundies:OperatingCashFlow Period: 2010-04-01 to 2011-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055/explain?concept=fundies%3AOperatingCashFlow&period=2011-03-31&surface=latest&period_type=duration&start=2010-04-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -159500000 Unit12 (2010-04-01 to 2011-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#804913 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.	Unit12 300,000 Exact value Exact value: 300000 Unit12 2010-04-01 – 2011-03-31: 300000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KV PHARMACEUTICAL CO /DE/ · 2011-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Capital Expenditure: 300000 Unit12 Concept: fundies:CapitalExpenditure Period: 2010-04-01 to 2011-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055/explain?concept=fundies%3ACapitalExpenditure&period=2011-03-31&surface=latest&period_type=duration&start=2010-04-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 300000 Unit12 (2010-04-01 to 2011-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1543338 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.	−Unit12 159.8 million Calculation and evidence -159500000 − 300000 Unit12 Exact free cash flow: -159800000 Unit12 2010-04-01 – 2011-03-31: -159500000 Unit12 · Inspect Operating Cash Flow · Source 2010-04-01 – 2011-03-31: 300000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KV PHARMACEUTICAL CO /DE/ · 2011-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Free cash flow: -159800000 Unit12 Concept: free-cash-flow Period: 2010-04-01 to 2011-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -159500000 Unit12 (2010-04-01 to 2011-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#804913 Filing: 000119312512271006 Input fundies:CapitalExpenditure: 300000 Unit12 (2010-04-01 to 2011-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1543338 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.
2012 2011-04-01 – 2012-03-31	−Unit12 102.3 million Exact value Exact value: -102300000 Unit12 2011-04-01 – 2012-03-31: -102300000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · KV PHARMACEUTICAL CO /DE/ · 2012-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Net Income: -102300000 Unit12 Concept: fundies:NetIncome Period: 2011-04-01 to 2012-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055/explain?concept=fundies%3ANetIncome&period=2012-03-31&surface=latest&period_type=duration&start=2011-04-01&unit=Unit12&dimensions= Input fundies:NetIncome: -102300000 Unit12 (2011-04-01 to 2012-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#808343 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.	−Unit12 169.3 million Exact value Exact value: -169300000 Unit12 2011-04-01 – 2012-03-31: -169300000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KV PHARMACEUTICAL CO /DE/ · 2012-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Operating Cash Flow: -169300000 Unit12 Concept: fundies:OperatingCashFlow Period: 2011-04-01 to 2012-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055/explain?concept=fundies%3AOperatingCashFlow&period=2012-03-31&surface=latest&period_type=duration&start=2011-04-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -169300000 Unit12 (2011-04-01 to 2012-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#805106 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.	Unit12 100,000 Exact value Exact value: 100000 Unit12 2011-04-01 – 2012-03-31: 100000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KV PHARMACEUTICAL CO /DE/ · 2012-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Capital Expenditure: 100000 Unit12 Concept: fundies:CapitalExpenditure Period: 2011-04-01 to 2012-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055/explain?concept=fundies%3ACapitalExpenditure&period=2012-03-31&surface=latest&period_type=duration&start=2011-04-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 100000 Unit12 (2011-04-01 to 2012-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1543527 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.	−Unit12 169.4 million Calculation and evidence -169300000 − 100000 Unit12 Exact free cash flow: -169400000 Unit12 2011-04-01 – 2012-03-31: -169300000 Unit12 · Inspect Operating Cash Flow · Source 2011-04-01 – 2012-03-31: 100000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KV PHARMACEUTICAL CO /DE/ · 2012-03-31 KV PHARMACEUTICAL CO /DE/ (edgar:57055) Free cash flow: -169400000 Unit12 Concept: free-cash-flow Period: 2011-04-01 to 2012-03-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/57055?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -169300000 Unit12 (2011-04-01 to 2012-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#805106 Filing: 000119312512271006 Input fundies:CapitalExpenditure: 100000 Unit12 (2011-04-01 to 2012-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/57055/000119312512271006/kva-20120331.xml#1543527 Filing: 000119312512271006 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

87 filings · 635 latest values · 635 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000057055, 57055, edgar:57055

Also known as K-V Pharmaceutical Co, KV PHARMACEUTICAL CO /DE/

KV PHARMACEUTICAL CO /DE/

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2012 2011-04-01 – 2012-03-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation